Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Cash from Investing Activities (2016 - 2022)

Historic Cash from Investing Activities for Spero Therapeutics (SPRO) over the last 6 years, with Q3 2022 value amounting to -$129000.0.

  • Spero Therapeutics' Cash from Investing Activities fell 10075.77% to -$129000.0 in Q3 2022 from the same period last year, while for Jun 2023 it was -$129000.0, marking a year-over-year decrease of 10046.59%. This contributed to the annual value of $33.8 million for FY2022, which is 34065.43% up from last year.
  • Latest data reveals that Spero Therapeutics reported Cash from Investing Activities of -$129000.0 as of Q3 2022, which was down 10075.77% from $50.0 million recorded in Q2 2022.
  • Over the past 5 years, Spero Therapeutics' Cash from Investing Activities peaked at $50.0 million during Q2 2022, and registered a low of -$72.6 million during Q3 2018.
  • Moreover, its 5-year median value for Cash from Investing Activities was $3.9 million (2020), whereas its average is -$88263.2.
  • In the last 5 years, Spero Therapeutics' Cash from Investing Activities soared by 39690.0% in 2019 and then crashed by 86950.48% in 2020.
  • Over the past 5 years, Spero Therapeutics' Cash from Investing Activities (Quarter) stood at $7.3 million in 2018, then plummeted by 156.25% to -$4.1 million in 2019, then tumbled by 869.5% to -$39.7 million in 2020, then skyrocketed by 41.43% to -$23.3 million in 2021, then surged by 99.45% to -$129000.0 in 2022.
  • Its last three reported values are -$129000.0 in Q3 2022, $50.0 million for Q2 2022, and -$16.1 million during Q1 2022.